VXRT News and Press, Vaxart Inc. From 02/06/19

Vaxart (NASDAQ: VXRT ): Q4 GAAP EPS of -$0.69. Revenue of $1.77M (+132.9% Y/Y) Press Release More news on: Vaxart, Inc., Earnings news and commentary, Healthcare stocks news, ,

Initiation of Two Norovirus Vaccine Trials Expected in 1H 2019 Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the fourth quarter and full year end...

Vaxart (NASDAQ: VXRT ): Q2 EPS of -$1.24 More news on: Vaxart, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the second quarter ended June 30, 2018 and provided a corporate update. "We are encouraged by the rece...

Vaxart, Inc. (Nasdaq:VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced publication of the comprehensive results of the previously disclosed Phase 1 clinical trial with its norovirus ora...